ALKEM LABORATORIES
|
|
BOM : 539523     NSE : ALKEM     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Aug 30,2024 |
Price(EOD): ₹ 6,167.80
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 73,766.89 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ALKEM LABORATORIES | 6% | 16.1% | 63.1% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 6% | 62.4% |
CIPLA | 3.9% | 7.3% | 33.9% |
DR REDDYS LABORATORIES | 1.2% | 4.2% | 20.1% |
ZYDUS LIFESCIENCES | 1.8% | -9.5% | 80.1% |
DIVIS LABORATORIES | 3.2% | 3.5% | 37.8% |
FUNDAMENTAL ANALYSIS OF ALKEM LABORATORIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ALKEM LABORATORIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
35.56
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 2,073.89 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 7.16
P/B Calculated based on Book Value of Rs 10,292.50 Cr
[Latest Year - Mar2024 - Consolidated Results ] 5.79
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 12,731.70 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
157% 50% 53% |
SHARE PRICE MOMENTUM OF ALKEM LABORATORIES
ALKEM LABORATORIES vs SENSEX
DEBT OF ALKEM LABORATORIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.09 0.12 0.26 0.16 |
0.12 0.14 0.3 0.19 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ALKEM LABORATORIES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ALKEM LABORATORIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
3.27% 51.41% 68.61% 80.71% |
2.16% 56.39% 75.53% 91.18% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
ALKEM LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 2.5% | 7.5% | 54.8% |
S&P BSE MID CAP | 1.5% | 1.8% | 58.4% |
S&P BSE LARGE MIDCAP | 1.4% | 1.2% | 38% |
S&P BSE 200 | 1.4% | 1.3% | 38% |
S&P BSE 250 LARGEMIDCAP | 1.3% | 1.1% | 38.2% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY PHARMA | 3.1% | 7.8% | 52.8% |
NIFTY HEALTHCARE | 2.9% | 6.5% | 52% |
NIFTY 200 | 1.4% | 1.4% | 38.5% |
NIFTY LARGE MIDCAP 250 | 1.4% | 1.1% | 43.3% |
NIFTY 500 | 1.4% | 1.3% | 40.2% |
You may also like the below Video Courses
FAQ about ALKEM LABORATORIES
Is ALKEM LABORATORIES good for long term investment?
As on Aug 30,2024, the Fundamentals of ALKEM LABORATORIES look Strong and hence it may be good for long term investment! See Financial Performance of ALKEM LABORATORIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ALKEM LABORATORIES UnderValued or OverValued?
As on Aug 30,2024, ALKEM LABORATORIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ALKEM LABORATORIES ?
As on Aug 30,2024, the Intrinsic Value of ALKEM LABORATORIES is Rs. 4,038.04 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 2,397.06
Fair Value [Median EV / Sales Model] : Rs. 4,103.84
Fair Value [Median Price / Sales Model] : Rs. 4,038.04
Estimated Median Fair Value of ALKEM LABORATORIES : Rs. 4,038.04
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.